Development of the Birmingham rheumatoid arthritis model: Past, present and future plans

Rheumatology

Volumn 50, Issue SUPPL. 4, 2011, Pages

  Barton, Pelham ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Biologic therapies; Cost effectiveness analysis; Modelling; NICE; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BIRMINGHAM RHEUMATOID ARTHRITIS MODEL; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; JOINT PROSTHESIS; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NONBIOLOGICAL MODEL; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT;

ADVISORY COMMITTEES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; ENGLAND; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, STATISTICAL; QUALITY OF LIFE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 80052199086     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker244     Document Type: Article

References (12)

1. NICE. http://www.nice.org.uk/aboutnice/howweworkdevnicetech/developing_nice_technology_appraisals.jsp (23 June 2011, date last accessed).
2. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6(21):1_110.
3. NICE Technology Appraisal 36. http://guidance.nice.org.uk/TA36 (31 January 2011, date last accessed).
4. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004;9: 110_8.
5. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8(11):1_91.
6. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004;8(18):1_105.
7. NICE Technology Appraisal 72. http://guidance.nice.org.uk/TA72 (31 January 2011, date last accessed).
8. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42):1_229.
9. NICE Technology Appraisal 130. http://guidance.nice.org.uk/TA130 (31 January 2011, date last accessed).
10. Barton P. Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients. Report to NICE, 2008 www.nice.org.uk/guidance/index. jsp?action=download&o=40512 (23 June 2011, date last accessed).
11. Malottki K, Barton P, Tsourapas A et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011;15(14):1_272.
12. NICE Technology Appraisal 195. http://guidance.nice.org.uk/TA195 (31 January 2011, date last accessed).